Artwork

Richard L. Miller에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Richard L. Miller 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Beyond the Trip: The Power of Group Therapy in Psychedelic Research – Brian Anderson

56:25
 
공유
 

Manage episode 359177464 series 2974664
Richard L. Miller에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Richard L. Miller 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

We take another deep dive into the world of psychedelic research with our guest, Brian Anderson, this week. Is there a place for group therapy with psychedelic medicine and treatment? Brian just concluded a clinical trial to study just that. Working with HIV/AIDS survivors, Brian and his team focused on the efficacy of group therapy following psychedelic treatment. The outcome was generally positive, not just for the trial participants but also for Brian and his fellow researchers, who have a renewed curiosity and optimism about what we can offer those seeking help from past trauma. The burning question on everyone's mind: will the government allow psychedelic research and trials to continue? Tune in to find out!

“I'm certainly more optimistic about how we can find ways to make psychedelic healing fit into conventional settings and do that in respectful and safe ways.”

Brian Anderson, MD MSc, is a psychiatrist and assistant clinical professor in the UCSF Department of Psychiatry and Behavioral Sciences. He is affiliated with the UC Berkeley Center for the Science of Psychedelics and UCSF Neuroscape. In 2018 he led a pilot clinical trial of psilocybin-assisted group therapy for demoralized long-term AIDS survivors. His research includes clinical trials as well as observational methods to assess the safety, clinical implementation, and regulation of the uses of psychedelics and other controlled substances.

Show notes:

* How Brian Anderson got involved with Psychedelic research

* Why research focuses on Psilocybin rather than LSD

* Is psychedelic group therapy in the near future?

* Brian’s study with HIV/AIDS survivors

* The impact dosage and preparatory work has on trail participants

* Some unwanted consequences to psilocybin treatments

* The headline of his trail

* Will the government allow psychedelic research and trails to continue?

Links and references:

* Psychedelic Wisdom

* Psychedelic Medicine

* So You Want to be a Psychedelic Researcher?

* clinicaltrials.gov

* Pragmatic Trial of Psilocybin Therapy in Palliative Care

Want the episode transcript and video? Join our Tribe!

Mind Body Health & Politics is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

https://www.mindbodyhealthpolitics.org/subscribe


This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mindbodyhealthpolitics.org/subscribe
  continue reading

289 에피소드

Artwork
icon공유
 
Manage episode 359177464 series 2974664
Richard L. Miller에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Richard L. Miller 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

We take another deep dive into the world of psychedelic research with our guest, Brian Anderson, this week. Is there a place for group therapy with psychedelic medicine and treatment? Brian just concluded a clinical trial to study just that. Working with HIV/AIDS survivors, Brian and his team focused on the efficacy of group therapy following psychedelic treatment. The outcome was generally positive, not just for the trial participants but also for Brian and his fellow researchers, who have a renewed curiosity and optimism about what we can offer those seeking help from past trauma. The burning question on everyone's mind: will the government allow psychedelic research and trials to continue? Tune in to find out!

“I'm certainly more optimistic about how we can find ways to make psychedelic healing fit into conventional settings and do that in respectful and safe ways.”

Brian Anderson, MD MSc, is a psychiatrist and assistant clinical professor in the UCSF Department of Psychiatry and Behavioral Sciences. He is affiliated with the UC Berkeley Center for the Science of Psychedelics and UCSF Neuroscape. In 2018 he led a pilot clinical trial of psilocybin-assisted group therapy for demoralized long-term AIDS survivors. His research includes clinical trials as well as observational methods to assess the safety, clinical implementation, and regulation of the uses of psychedelics and other controlled substances.

Show notes:

* How Brian Anderson got involved with Psychedelic research

* Why research focuses on Psilocybin rather than LSD

* Is psychedelic group therapy in the near future?

* Brian’s study with HIV/AIDS survivors

* The impact dosage and preparatory work has on trail participants

* Some unwanted consequences to psilocybin treatments

* The headline of his trail

* Will the government allow psychedelic research and trails to continue?

Links and references:

* Psychedelic Wisdom

* Psychedelic Medicine

* So You Want to be a Psychedelic Researcher?

* clinicaltrials.gov

* Pragmatic Trial of Psilocybin Therapy in Palliative Care

Want the episode transcript and video? Join our Tribe!

Mind Body Health & Politics is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

https://www.mindbodyhealthpolitics.org/subscribe


This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mindbodyhealthpolitics.org/subscribe
  continue reading

289 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드